Cerebral venous sinus thrombosis (CVST) is a particular type of cerebrovascular disease characterised by increased intracranial pressure due to impaired cerebral venous drainage and absorption of cerebrospinal fluid. The incidence of CVST is 2--5/10 000 000/year, accounting for 0.5%--1% of all stroke.[@R1] Recently, the incidence of CVST has been rising with the advent of diagnostic techniques. Two studies in Iran have reported CVST affects 12.3--13.49/10 000 000/year,[@R3] and another study in Saudi Arabia has shown that CVST affects 70/10 000 000/year.[@R11] Moreover, the incidence of CVST has also been increasing in Europe and America, approximately 13.2--15.7/10 000 000/year.[@R12] CVST occurs in neonates and juveniles with a frequency of 6.7/10 000 000/year.[@R1] The international study of cerebral venous thrombosis has reported 487 of 624 cases occur in patients aged \<50 years.[@R16] During pregnancy, the incidence of CVST is 100/10 000 000, accounting for 5%--20% of all CVST.[@R4] The epidemiological data of CVST in China are scarce. Nevertheless, CVST is not uncommon in China, especially in women taking oral contraceptives or in the perinatal period. CVST can affect superficial cerebral veins, deep cerebral veins or dural venous sinuses. The isolated thrombosis of superficial cerebral veins is rare. The involvement of superficial veins, for the most part, is caused by the thrombosis of dural venous sinuses. The thrombosis of deep cerebral veins usually occurs in the internal cerebral vein and vein of Galen. About 60% of patients with CVST involve multiple dural venous sinuses, with the superior sagittal sinus the most frequently affected. As there are multiple anatomical anastomoses between cerebral veins and dural venous sinuses, clinical manifestations vary from an asymptomatic state to death, depending on the site of thrombosis and collateral circulation.

This document is the executive summary, and update of the guideline of CVST by Chinese Stroke Association in 2019. The full text of this guideline is available in the [online supplementary material](#SP1){ref-type="supplementary-material"}. The intended audiences of this guideline are physicians of neurology and other related disciplines, providing references for the clinical management of CVST in China.10.1136/svn-2020-000358.supp1Supplementary data

Part 1: diagnostic evaluation {#s1}
=============================

CVST can directly increase pressure of venules and capillaries, and can increase intracranial pressure by reducing the absorption of cerebrospinal fluid, leading to the decrease of cerebral artery perfusion, destruction of blood-brain barrier, ischaemic damage or cerebral parenchymal haemorrhage. Therefore, clinical manifestations of CVST mainly depend on the location, nature, extent of venous (sinus) thrombosis and the degree of secondary brain damage. The diagnostic flow chart is shown in [figure 1](#F1){ref-type="fig"}.

![The proposed algorithm for the diagnosis of cerebral venous sinus thrombosis (CVST). CTV, compute tomography venography. MRV, magnetic resonance venography. MRV, magnetic resonance venography. DSA, digital substraction angiography. CSF, cerebrospinal fluid.](svn-2020-000358f01){#F1}

History and clinical manifestations {#s2}
===================================

Recommendation {#s2-1}
--------------

1.  Vigilance should be maintained for CVST. The possibility of CVST should be considered in patients presented with headache, papilloedema or increased intracranial pressure with unknown cause. The screening for CVST is reasonable in patients presented with unexplained seizures (including eclampsia), focal brain injury, different levels of unconsciousness, cognitive disorders, psychosis or dural arteriovenous fistula. (Class I, Level of Evidence C).

Auxiliary examination {#s3}
=====================

Recommendation {#s3-1}
--------------

1.  Routine blood tests consisting of a complete blood count, chemistry panel, prothrombin time, activated partial thromboplastin time, plasma protein and connective tissue disease or cancer markers are recommended in patients with suspected CVST. (Class I, Level of Evidence C)

2.  Screening for potential prothrombotic factors (eg, antithrombin III, protein C or protein S deficiency, factor V Leiden, prothrombin mutation, anticardiolipin antibody, lupus anticoagulant) is recommended in patients with undetermined aetiology, recurrent CVST or a family history of venous thrombosis, to identify the root cause and select appropriate preventive and therapeutic strategies. (Class IIb, Level of Evidence C)

3.  An elevated D-dimer level is considered to support the diagnosis of CVST, but a normal D-dimer level should not exclude CVST, especially in patients presented with isolated headache or chronic symptoms. (Class IIa, Level of Evidence B)

4.  Lumbar puncture may identify increased intracranial pressure and underlying causes of CVST (eg, infections). (Class IIa, Level of Evidence C)

5.  CT/CTV and MRI/MRV are recommended in the initial imaging evaluation of patients with suspected CVST. MRI/MRV is able to diagnose most of CVST, and is recommended as the best non-invasive imaging in the follow-up of CVST. Contrast-enhanced (CE) MRV is more reliable than time-of-flight MRV. (Class IIa, Level of Evidence C)

6.  SWI and T2\*-GRE imaging improve the diagnosis of CVST, especially in patients with isolated cortical venous thrombosis or during acute stage. (Class IIa, Level of Evidence C)

7.  CE-3D-MPRAGE and 3D-T1-SPACE are sensitive in detecting isolated cortical venous thrombosis and non-thrombotic sinus stenosis. These techniques may be considered in the differentiation of CVST from other conditions (eg, dural sinus stenosis). (Class IIa, Level of Evidence C)

8.  DSA is recommended if the initial imaging evaluation by MRV or CTV is inconclusive or endovascular therapy is being considered. The shortage of DSA in detecting isolated cortical venous thrombosis, and the risks of increased intracranial pressure caused by invasive and improper operation should be considered. (Class IIa, Level of Evidence C)

9.  Venous pressure measurements via retrograde venography may be performed in patients with intracranial hypertension and dural venous stenosis. Endovascular therapy may be considered in patients with significantly increased pressure gradient between the proximal and distal segment to the stenosis. (Class IIa, Level of Evidence C)

10. A follow-up CTV/MRV is recommended in patients with CVST with persistent or evolving symptoms despite the initial imaging results. (Class I, Level of Evidence C)

11. A follow-up CTV/MRV at 3--6 months is reasonable to evaluate the recanalisation of dural sinuses and cortical veins. (Class IIa, Level of Evidence C)

Causes and risk factors for CVST {#s4}
================================

Recommendation {#s4-1}
--------------

1.  The risk factors and causes of CVST are complicated and diverse. It is recommended to screen for the risk factors contributed to prothrombotic conditions and exclude the possibility of infections associated with CVST. (Class I, Level of Evidence B)

Part 2: treatment of CVST {#s5}
=========================

The main treatment of CVST is anticoagulation therapy with either intravenous unfractionated heparin (UFH) or subcutaneous low-molecular weight heparin (LMWH). After the acute stage of CVST, oral anticoagulants such as warfarin should be used for at least 3--6 months. Recently, an exploratory, prospective, randomised trial (RE-SPECT CVT) compared the efficacy and safety of dabigatran with warfarin in patients with CVST for 24 weeks. The result demonstrated both dabigatran and warfarin were safe and effective for preventing recurrent venous thrombotic events in patients with CVST.[@R17] However, the efficacy of endovascular treatment has not been proved until now. The flow chart of CVST treatment is shown in [figure 2](#F2){ref-type="fig"}.

![The proposed algorithm for the treatment of cerebral venous sinus thrombosis (CVST). INR, international normalised ratio; LMWH, low-molecular weight heparin; UFH, unfractionated heparin.](svn-2020-000358f02){#F2}

Anticoagulation therapy {#s6}
=======================

Recommendation {#s6-1}
--------------

1.  Anticoagulation therapy should be initiated in patients with CVST immediately. (Class I, Level of Evidence B) The safety and efficacy of LMWH is slightly superior to UFH. (Class IIa, Level of Evidence B) LMWH is recommended for the acute management of CVST. The therapeutic dosage of LMWH is 0.4--0.6 mL, injected subcutaneously twice a day. If UFH is used, the initial treatment should at least double the activated partial thromboplastin time, lasting for 1--4 weeks. CVST with minor intracranial haemorrhage or intracranial hypertension is not an absolute contradiction to anticoagulation therapy. (Class IIb, Level of Evidence B)

2.  Oral anticoagulants should be initiated after the acute stage of CVST. The most commonly used agent is warfarin, with a target international normalised ratio (INR) of 2--3. The duration of treatment depends on the tendency to thrombosis and the risk of recurrence. (Class IIa, Level of Evidence C). Warfarin is recommended to maintain 3--6 months to prevent the recurrence of CVST and other venous thromboembolic events. (Class IIa, Level of Evidence C) It is undetermined whether recanalisation of the occluded veins or dural sinuses can be considered as an indication for withdrawal of oral anticoagulants. (Class III, Level of Evidence C)

3.  Dabigatran may be considered in patients with CVST unsuitable for warfarin. (Class IIa, Level of Evidence B) (New recommendation) Further studies are needed to determine the efficacy of other new oral anticoagulants in CVST. (Class IIb, Level of Evidence C)

Endovascular treatment {#s7}
======================

Recommendation {#s7-1}
--------------

1.  Current evidence is not sufficient to recommend the application of intrasinus thrombolysis or mechanical thrombectomy in severe CVST. However, mechanical thrombectomy can be considered in patients with severe CVST after adequate anticoagulation has failed and there is a need to prevent or treat brain herniation. (Class IIb, Level of Evidence C)

2.  Venous pressure measurements via retrograde venography may be performed in patients with intracranial hypertension and dural venous stenosis. Intrasinus stenting may be considered if the pressure gradient between proximal and distal segment to the stenosis is beyond 8--10 mm Hg. (Class IIb, Level of Evidence C)

3.  The long-term antithrombotic treatment after the sinus stenting is not clear. According to clinical practice in arterial stenting, it is reasonable to use dual antiplatelet therapy for the first 3 months followed by single antiplatelet therapy for maintenance. (Class IIb, Level of Evidence C)

Treatment of CVST during pregnancy {#s8}
==================================

Recommendation {#s8-1}
--------------

1.  LMWH is recommended in women with CVST during pregnancy. The safety of LMWH is superior to UFH. Subcutaneous injection of LMWH is recommended throughout the pregnancy (0.4 mL, twice a day), followed by LMWH or warfarin with a target INR of 2--3 for at least 6 weeks postpartum. The total duration of treatment is no less than 6 months. (Class I, Level of Evidence C)

Aetiological treatment {#s9}
======================

Recommendation {#s9-1}
--------------

1.  It is recommended to seek and treat the potential causes. Administration of appropriate and adequate antibiotics should be initiated immediately in patients with infection and CVST, as well as surgical removal of sources of infection. (Class I, Level of Evidence C)

2.  Patients with CVST with factor V Leiden gene mutation, protein C or protein S deficiency may benefit from long-term therapy with oral anticoagulants. (Class IIa, Level of Evidence C)

3.  It is recommended to reduce or avoid the use of oral contraceptives, especially in female patients with a previous history of CVST. (Class I, Level of Evidence C)

4.  Pregnancy is not contraindicated in female patients with a history of CVST, but patients should be informed of the high risk of recurrent CVST or loss of pregnancy. (Class IIa, Level of Evidence C)

Management of complications {#s10}
===========================

Recommendation {#s10-1}
--------------

1.  Patients with severe intracranial hypertension and impending cerebral herniation should be treated immediately. Use of decompressive craniectomy, ventriculoperitoneal shunt or haematoma evacuation may be considered. (Class IIa, Level of Evidence C)

2.  Patients with increased intracranial pressure and progressive visual loss should be treated early to save the vision. Decompressive surgery includes optic nerve sheath fenestration and ventriculoperitoneal shunt. (Class IIa, Level of Evidence C)

3.  It is reasonable to initiate short-term dehydration therapy with mannitol or furosemide, to gain time for surgery in patients with intracranial hypertension, progressive visual loss or cerebral herniation. Excessive dehydration is prohibited as it can lead to blood concentration and aggravation of CVST. Acetazolamide may be considered in certain patients to reduce intracranial pressure by decreasing the secretion of cerebrospinal fluid. (Class IIb, Level of Evidence C)

4.  In patients with a first seizure and parenchymal lesion, antiepileptic therapy should be initiated immediately. (Class I, Level of Evidence B) In patients with a first seizure without parenchymal lesion, early initiation of antiepileptic drugs may be beneficial. (Class III, Level of Evidence C) Prophylactic use of antiepileptic drugs in patients with CVST is not beneficial. (Class III, Level of Evidence C)

5.  The treatment of dural arteriovenous fistula induced by CVST can refer to the general principles of dural arteriovenous fistula. More attention should be given to the establishment and protection of cerebral venous drainage. (Class IIb, Level of Evidence C)

Other treatment {#s11}
===============

Recommendation {#s11-1}
--------------

1.  In patients with clinical deterioration despite adequate anticoagulation therapy, and without severe intracranial haemorrhage, direct intrasinus thrombolysis can be carefully performed under close supervision. (Class IIb, Level of Evidence C) Current evidence does not support the use of systemic thrombolysis in CVST. (Class III, Level of Evidence C)

2.  Current evidence does not support the routine use of antiplatelet drugs or de-fibrin therapy in CVST, unless it is indicated for other underlying diseases. (Class III, Level of Evidence C)

3.  Routine use of steroid in CVST is not beneficial, unless it is indicated for other underlying diseases. (Class III, Level of Evidence B)

4.  It is recommended to use antibiotics in patients with CVST and infection for 3--8 weeks. (Class I, Level of Evidence C)

Part 3: secondary prevention of CVST {#s12}
====================================

Recommendation {#s12-1}
--------------

1.  If patients with a history of CVST have a recurrent and constant headache, it is necessary to evaluate the recurrence of CVST and pay attention to intracranial hypertension. (Class I, Level of Evidence C)

2.  To prevent recurrence of CVST, it is important to eliminate the root cause. (Class I, Level of Evidence C) It is beneficial to seek and treat prothrombotic conditions, such as protein C, protein S deficiency, antiphospholipid syndrome and factor V Leiden mutation, for preventing recurrence of CVST in certain patients. (Class IIa, Level of Evidence C)

3.  Long-term oral anticoagulants may be considered in patients with recurrent CVST and severe thrombophilia, with a target INR of 2--3. (Class IIa, Level of Evidence C)
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